Friday, 16 October 2026European Markets

PARROT Stock Bearish Momentum With A 10% Drop So Far On Friday

Loading stream...

parrot (parro.pa), a giant in the world of french drone and professional software services, experienced a slump in its fortunes with its share price falling by 10% to eur3.96, taking a departure from their two previous sessions of gains. despite a relatively stable performance of the cac 40 index with only minor fluctuations (down 0.19% at eur7,450.94), parrot is embarking on a different course, showing signs of decline.

impact on investors

with parrot's last closing price standing at eur4.40, it represents an annual low by 21.43%. this situation may pose a threat to investors who base their decisions on stocks near annual peak levels as potential buying signals, causing a negative impact.

parrot's earnings and returns

the company's previous trailing annual earnings per share (eps) revealed a negative eur-0.66, aligning with significant losses. in addition, their negative return on equity (roe)—a measure of profitability with respect to shareholders' equity—stands at -21.39% over the past year, turning on another red light for potential investors.

stock volatility

notwithstanding the recent plunges, parrot's stock volatility over the last week, month, and quarter has managed to stay relatively low, being under 3% across all three periods. this suggests a steady investor sentiment towards this stock, although recent price drops in parro.pa could potentially alter this stability.

stock condition

a point worth noting is that as per the stochastic oscillator, parrot's stock has entered the oversold territory. a reading below 20 in the stochastic oscillator often indicates an oversold condition and might signal an appealing buying opportunity for investors looking for a bargain. still, while this tool may offer some guidance, it should not be used in isolation when making investment decisions due to the complex mesh of economic, financial, and corporate factors affecting market trends.

more news about parrot (parro.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com